Kisspeptin-10 dosing & administration
A powerful reproductive hormone regulator that acts like the master switch for your body's fertility system—triggering the release of hormones that control everything from ovulation to testosterone production.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
3 documented dose levels — separate regimens, not a titration schedule
50 mcg per injection
Frequency
Once daily
Duration
1-2 weeks
Conservative subcutaneous entry dose used in research practice; kisspeptin-10 has a very short half-life (~4 min IV) so effects are pulse-like [1].
100 mcg per injection
Frequency
Once daily
Duration
4-6 weeks
Common research/practice subcutaneous dose; roughly approximates the ~1 mcg/kg level shown to maximally stimulate LH in men [6].
100-200 mcg per injection
Frequency
Once or twice daily
Duration
4-6 weeks
Upper end of the practice range; higher kisspeptin-10 doses can blunt the LH response (a ceiling/desensitization effect was seen above ~1 mcg/kg) so escalating beyond this is not advised [6].
Timing
Best time to take
Morning administration works well for most goals, as it aligns with your body's natural cortisol awakening response [23] and gives hormones time to rise during your active hours. For fertility protocols, timing may be adjusted based on cycle phase [11][14].
With food?
Kisspeptin can be taken regardless of food timing. Injection absorption isn't significantly affected by meals, so choose whatever time works best for your routine.
If stacking
If combining with other peptides like PT-141 for sexual health, space injections by at least 30 minutes. Don't combine with GnRH antagonists as they directly counteract kisspeptin's mechanism. [17] Can be used alongside clomiphene for enhanced reproductive hormone support.
Adjusting your dose
Increase if
- You've completed starting doses with no side effects and want stronger hormonal response
- Blood work shows minimal LH/FSH response to current dose
- Working with a physician on fertility protocols requiring more robust stimulation
Decrease if
- You experience persistent flushing or feeling overheated
- Headaches don't resolve after the first few days
- You notice heart racing or palpitations
- Blood pressure increases significantly
Signs of right dose
- Noticeable improvement in energy and well-being (related to hormone optimization)
- For men: improved morning erections and libido
- Blood work showing healthy LH, FSH, and sex hormone levels
- No significant side effects between doses
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (just under the skin)—the most practical method for self-administration with good absorption
Best sites
Storage
Before reconstitution
Keep your kisspeptin powder in the refrigerator (36-46°F / 2-8°C) for short-term storage or in the freezer (-4°F / -20°C) for long-term storage. Kisspeptin-10 is a relatively stable peptide when lyophilized, but protect it from light and moisture.
After reconstitution
Once mixed with bacteriostatic water, refrigerate at 36-46°F (2-8°C). Never freeze the reconstituted solution. Use within 14-21 days—kisspeptin-10's short half-life means the reconstituted peptide may degrade faster than longer peptides.
Signs of degradation — discard the vial
Sample daily schedule
Morning (7-9 AM)
50-100 mcg injection
Site: Rotate between belly, thigh, and arm
Morning dosing aligns with natural cortisol rhythm and allows hormonal effects during active hours. For fertility protocols, timing may be adjusted based on cycle monitoring.
Safety
Is it safe?
Side effects
Commonly reported: Flushing or warmth, Injection site reactions, Mild headache
Less common: Temporary heart rate increase, Dizziness
Stop and seek help if
- Any signs of allergic reaction—stop immediately and seek medical help
- Persistent flushing or overheating that doesn't improve with dose reduction
- Significant increases in blood pressure or heart rate
- Worsening of any hormone-sensitive condition
- Unexpected breast tissue changes in men (gynecomastia symptoms)
- Your treatment protocol is complete or goals achieved
Kisspeptin-10 is a research compound, not an FDA-approved medication. Never start, stop, or change your dosing without guidance from a qualified healthcare provider. This information is for educational purposes only—not medical advice.
Flagged pairings
- Gonadorelin — Both stimulate GnRH/gonadotropin release. Using together may cause excessive hormonal stimulation. Generally not needed together as mechanisms overlap.
- GnRH antagonists (Cetrorelix, Ganirelix) — These directly block the receptor that kisspeptin ultimately activates. Do not combine—they work against each other.
- Testosterone replacement therapy — Exogenous testosterone suppresses LH release, which is what kisspeptin stimulates. Using together defeats the purpose of kisspeptin.
Published research
What the studies show
Mills EG, Ertl N, Wall MB, et al. · 2023
This randomized clinical trial found that kisspeptin significantly enhanced brain activity in sexual processing regions and increased penile tumescence by up to 56% in men with low sexual desire. Participants also reported improved happiness about sex—suggesting kisspeptin could become the first pharmacological treatment for male HSDD.
Thurston L, Hunjan T, Ertl N, et al. · 2022
Kisspeptin modulated brain regions involved in sexual and facial attraction processing in women with HSDD. The effects correlated with reduced sexual aversion and improved responses to attractive stimuli, laying groundwork for potential female HSDD treatment.
Abbara A, Islam R, Clarke SA, et al. · 2018
Compared to traditional hCG trigger, kisspeptin reduced ovarian volume by 3-fold and virtually eliminated OHSS symptoms. The odds of developing OHSS were 33x lower with kisspeptin compared to hCG, making it a much safer option for high-risk IVF patients.
Mills EG, Thurston L, Yang L, et al. · 2025
A placebo-controlled study of 95 participants confirmed that kisspeptin robustly stimulates LH release while having no effect on anxiety, cortisol, blood pressure, or heart rate. This provides reassurance that kisspeptin-based therapies won't cause psychological side effects.
Mills EG, Silva MSB, Delli V, et al. · 2025
This breakthrough study showed that intranasal kisspeptin effectively stimulates LH release in healthy men, women, and patients with hypothalamic amenorrhea—without any adverse events. This non-invasive route could transform kisspeptin into a practical take-home treatment for reproductive disorders.
George JT, Veldhuis JD, Roseweir AK, Newton CL, Faccenda E, Millar RP, Anderson RA · 2011
IV bolus kisspeptin-10 across 0.01-3.0 mcg/kg produced dose-dependent LH rise; 1 mcg/kg gave maximal stimulation (peak LH 12.4 IU/L at 30 min), while 3 mcg/kg produced a reduced response.
Dhillo WS, Chaudhri OB, Patterson M, et al. · 2005
A 90-minute IV infusion of kisspeptin-54 in male volunteers significantly raised plasma LH (10.8 vs 4.2 U/L), FSH (3.9 vs 3.2 U/L) and testosterone (24.9 vs 21.7 nmol/L) compared with saline. Plasma half-life of kisspeptin-54 was 27.6 min.
Seminara SB, Messager S, Chatzidaki EE, et al. · 2003
Loss-of-function mutations in GPR54 — the kisspeptin receptor — cause autosomal recessive idiopathic hypogonadotropic hypogonadism, an absence of pubertal development, in humans; Gpr54-deficient mice show the same phenotype while remaining responsive to exogenous GnRH.
Kotani M, Detheux M, Vandenbogaerde A, et al. · 2001
Kisspeptins derived from the KiSS-1 gene product bind GPR54 with low-nanomolar affinity and stimulate PIP2 hydrolysis, Ca2+ mobilisation, arachidonic acid release and ERK1/2 and p38 MAP kinase phosphorylation — the Gq-coupled signalling arm of the receptor.
Lehman MN, Coolen LM, Goodman RL · 2010
Arcuate nucleus neurons co-expressing kisspeptin, neurokinin B and dynorphin (KNDy cells) are conserved from rodents to humans, form a reciprocally interconnected network projecting to GnRH cell bodies and terminals, and are positioned to serve as a component of the GnRH pulse generator; altered KNDy peptides are implicated in polycystic ovarian syndrome.
Dhillo WS, Chaudhri OB, Thompson EL, et al. · 2007
Subcutaneous bolus kisspeptin-54 raised plasma LH in every phase of the menstrual cycle, but the effect was far greatest in the preovulatory phase (mean LH rise 20.64 IU/L) and least in the follicular phase (0.12 IU/L).
Jayasena CN, Nijher GMK, Chaudhri OB, et al. · 2009
In women with hypothalamic amenorrhea, a single subcutaneous injection of kisspeptin-54 potently raised LH (+24.0 IU/L) and FSH (+9.1 IU/L); after 14 days of twice-daily injection the response had fallen to +2.5 and +0.5 IU/L, while responsiveness to GnRH was retained.
Abbara A, Jayasena CN, Christopoulos G, et al. · 2015
Phase 2 trial at Hammersmith Hospital (Imperial College London) in 60 women at high risk of OHSS, 37% of whom had PCOS. A single kisspeptin-54 injection produced oocyte maturation in 95% and live birth in 45% per transfer; no woman developed moderate, severe or critical OHSS, and kisspeptin-54 was well tolerated with no adverse events attributed to the injection.
Jayasena CN, Nijher GMK, Comninos AN, et al. · 2011
IV bolus kisspeptin-10 raised LH and FSH in men and in women during the preovulatory phase, but IV bolus, subcutaneous bolus and IV infusion all failed to raise gonadotropins in women during the follicular phase. Reported plasma half-life of kisspeptin-10 was approximately 3.8 minutes in men.
Mead EJ, Maguire JJ, Kuc RE, Davenport AP · 2007
GPR54 mRNA and protein were localised to vascular smooth muscle and endothelium of human aorta, coronary artery and umbilical vein, and kisspeptin-10, -13 and -54 all acted on isolated human vessel rings — establishing a direct action of kisspeptin on the human vasculature.
Chan YM, Lippincott MF, Butler JP, et al. · 2014
Every subject with abiding idiopathic hypogonadotropic hypogonadism failed to mount a GnRH-induced LH response to an IV kisspeptin bolus that reliably produces one in healthy men and luteal-phase women; the one subject whose hypogonadotropism had reversed responded robustly.
Plant TM, Ramaswamy S, Dipietro MJ · 2006
Hourly IV kisspeptin-10 pulses evoked a sustained train of LH discharges in the juvenile monkey; concomitant treatment with the GnRH receptor antagonist acyline abolished kisspeptin-10-induced LH release, showing the response is wholly GnRH-dependent.
Yeung AC, Phylactou M, Koysombat K, et al. · 2026
Acute subcutaneous kisspeptin-10 infusion dose-dependently raised LH, FSH and testosterone in healthy men. Five days of continuous infusion left gonadotropins no different from vehicle, whereas daily intermittent dosing (8 h on, 16 h off) sustained the gonadotropin rise across 12 days.
Massachusetts General Hospital; ClinicalTrials.gov · 2024
Phase 2 study of kisspeptin 112-121 (kisspeptin-10) given intravenously (n=21) and subcutaneously (n=15). Posted adverse events include headache in 5/21 IV and 2/15 subcutaneous participants, dizziness in 1/21 and 1/15, and pain of skin in 3/21 and 2/15.
Seminara SB; Massachusetts General Hospital; ClinicalTrials.gov · 2026
Phase 2 study of pulsatile kisspeptin 112-121 in hypogonadotropic hypogonadism (n=18). Posted adverse events include hot flashes (vascular disorders) in 1/18 and dizziness in 1/18.
Pfizer Laboratories Div Pfizer Inc · 2017
Mechanism of action: sildenafil inhibits PDE5, raising cGMP in the corpus cavernosum, producing smooth muscle relaxation and inflow of blood. The label states sildenafil at recommended doses has no effect in the absence of sexual stimulation.
Azurity Pharmaceuticals, Inc. · 2025
With large doses of exogenous androgens, spermatogenesis may be suppressed through feedback inhibition of the hypothalamic-pituitary-testicular axis and of pituitary FSH, with adverse effects on sperm count; the label notes reduced fertility in some men on testosterone replacement therapy and reports of testicular atrophy, subfertility and infertility.
Pruessner JC, Wolf OT, Hellhammer DH, et al. · 1997
Salivary free cortisol rises sharply in the period immediately after awakening — the cortisol awakening response — and this post-waking rise is a stable, reproducible marker of adrenocortical activity within individuals.
Head to head
Kisspeptin-10 compared
Studied for
Conditions Kisspeptin-10 has been researched in
Want the full picture?
The complete Kisspeptin-10 research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.